Anbio Biotechnology (NNNN) Cash & Equivalents (2023 - 2025)

Anbio Biotechnology has reported Cash & Equivalents over the past 3 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $7.8 million for Q4 2025, down 33.96% from a year ago — trailing twelve months through Dec 2025 was $7.8 million (down 33.96% YoY), and the annual figure for FY2025 was $7.8 million, down 33.96%.
  • Cash & Equivalents for Q4 2025 was $7.8 million at Anbio Biotechnology, down from $11.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for NNNN hit a ceiling of $11.8 million in Q4 2024 and a floor of $7.8 million in Q4 2025.
  • Median Cash & Equivalents over the past 3 years was $9.7 million (2023), compared with a mean of $9.7 million.
  • Biggest five-year swings in Cash & Equivalents: grew 21.4% in 2024 and later tumbled 33.96% in 2025.
  • Anbio Biotechnology's Cash & Equivalents stood at $9.7 million in 2023, then rose by 21.4% to $11.8 million in 2024, then tumbled by 33.96% to $7.8 million in 2025.
  • The last three reported values for Cash & Equivalents were $7.8 million (Q4 2025), $11.8 million (Q4 2024), and $9.7 million (Q4 2023) per Business Quant data.